⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Consult your healthcare provider before starting any medication or interpreting medical test results on your own.
When you start a GLP-1 medication — semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro) — your doctor will order blood tests at the start, at 3 months, and every 6 to 12 months thereafter. You will receive a report from SRL, Metropolis, Thyrocare, Dr Lal PathLabs, or your hospital's in-house lab. You will see columns of numbers, reference ranges marked as "normal," and occasional red or flagged values.
The problem: Indian lab reference ranges are inconsistent, often calibrated to Western populations, and sometimes show a value as "normal" when your doctor considers it a concern requiring action. This guide explains the most important values for GLP-1 users, what Indian lab ranges actually mean, and how to have a productive conversation with your doctor about your results.
Indian diagnostic labs are regulated by NABL (National Accreditation Board for Testing and Calibration Laboratories) but set their own reference intervals. These intervals are typically derived from Western population studies, which creates three specific problems for Indian patients:
1. BMI thresholds are calibrated to Western bodies. Internationally, obesity is defined as BMI over 30. But the WHO Asian-specific BMI cutoffs — adopted by RSSDI and Indian endocrinologists — define overweight at BMI 23 and obesity at BMI 25. This matters because Indians develop metabolic complications (diabetes, fatty liver, hypertension) at lower body weights than Europeans.
2. "Normal" does not always mean "optimal." A patient's HbA1c of 6.3% is within the normal range on most Indian lab reports (which mark "normal" as below 6.4%). But for a GLP-1 patient with existing prediabetes, 6.3% is still a concern requiring active monitoring. Lab normals are population averages, not treatment targets.
3. Vitamin B12 ranges are frequently wrong for Indians. Most Indian labs list the lower limit of normal B12 as 200 pg/mL. However, neurological symptoms of B12 deficiency can occur at levels up to 300 to 400 pg/mL. Indian vegetarians — who make up over 30% of GLP-1 users — are chronically low in B12 and may be falsely reassured by a lab report saying "normal."
HbA1c measures your average blood sugar over 3 months. It is the primary monitoring test for GLP-1 therapy.
| HbA1c Value | What Indian Labs Usually Say | What It Actually Means for GLP-1 Users |
|---|---|---|
| Below 5.7% | Normal | No diabetes; excellent control |
| 5.7% to 6.4% | Borderline or normal | Prediabetes range; GLP-1 actively working to prevent progression |
| 6.5% or above | High / Diabetes | Diagnosis threshold for Type 2 diabetes |
| Below 7.0% | Often not flagged | Target for most diabetic patients on GLP-1 treatment |
| Below 6.5% | Not flagged | Stricter target for younger patients or those on combination therapy |
What GLP-1 does: Semaglutide 1 mg reduces HbA1c by an average of 1.5 percentage points. Tirzepatide 15 mg reduces it by up to 2.4 percentage points. Expect to see improvement in 3 to 6 months.
What can falsely affect HbA1c in Indian patients: Iron-deficiency anaemia (very common in Indian women), haemoglobin variants (HbS, HbC, HbE — more common in certain communities), and chronic kidney disease can all give falsely high or low HbA1c values. If your HbA1c seems inconsistent with your glucose readings, ask your doctor about fructosamine testing as an alternative.
| Test | Normal (Indian RSSDI/IDF) | Prediabetes | Diabetes |
|---|---|---|---|
| Fasting glucose | Below 100 mg/dL | 100 to 125 mg/dL | 126 mg/dL or above |
| 2-hour postprandial | Below 140 mg/dL | 140 to 199 mg/dL | 200 mg/dL or above |
On GLP-1: Fasting glucose typically improves significantly within 4 to 8 weeks. Postprandial glucose improves faster because GLP-1 stimulates insulin release in response to meals. If your fasting glucose is improving but postprandial is not, this may indicate your dose needs adjustment.
Indian context: Many Indian labs still measure glucose in mg/dL. If you see mmol/L on your report, multiply by 18 to convert (e.g., 7.0 mmol/L = 126 mg/dL).
Indian labs typically report: Total cholesterol, LDL (low-density lipoprotein), HDL (high-density lipoprotein), and Triglycerides (TG).
| Marker | Lab "Normal" Range | Target for GLP-1 Users with Diabetes |
|---|---|---|
| Total cholesterol | Below 200 mg/dL | Below 180 mg/dL preferred |
| LDL | Below 130 mg/dL | Below 100 mg/dL; below 70 mg/dL if high cardiovascular risk |
| HDL (men) | Above 40 mg/dL | Above 50 mg/dL preferred |
| HDL (women) | Above 50 mg/dL | Above 60 mg/dL preferred |
| Triglycerides | Below 150 mg/dL | Below 100 mg/dL preferred |
What GLP-1 does to lipids: Semaglutide reduces LDL by approximately 5%, reduces triglycerides by 20 to 25%, and modestly raises HDL. Tirzepatide shows more pronounced triglyceride reduction. These improvements typically appear by 3 to 6 months and are more notable as weight loss progresses.
Important Indian context: Indians have a genetic tendency toward elevated triglycerides and low HDL — a pattern called "atherogenic dyslipidaemia" — even at normal LDL levels. Your lab report may show LDL as "normal" (below 130 mg/dL) while your triglycerides and HDL indicate significant cardiovascular risk. Ask your doctor specifically about your non-HDL cholesterol (total cholesterol minus HDL), which is a better risk predictor for Indians.
| Enzyme | Typical Lab Normal (Men) | Typical Lab Normal (Women) | Concern Threshold |
|---|---|---|---|
| ALT (SGPT) | 7 to 56 U/L | 7 to 45 U/L | Above 3x the upper limit of normal |
| AST (SGOT) | 10 to 40 U/L | 10 to 35 U/L | Above 3x the upper limit of normal |
| ALP | 44 to 147 U/L | 33 to 130 U/L | Context-dependent; elevated in bone disease |
What GLP-1 does to liver enzymes: GLP-1 medications improve fatty liver disease (NAFLD/MASLD). Many patients see their elevated liver enzymes normalise within 6 to 12 months of therapy. A modest temporary rise in ALT (by 10 to 20 U/L) can occasionally occur at the start of GLP-1 therapy, particularly in patients with pre-existing fatty liver — this is usually not a cause for concern but should be monitored.
When to act: If ALT or AST is more than 3 times the upper limit of normal (above approximately 150 U/L for ALT), notify your doctor. This level requires investigation.
Indian context: NAFLD affects approximately 38% of Indians — higher than the global average. Many Indian patients start GLP-1 medications with mildly elevated liver enzymes. Improvement in these enzymes is one of the expected benefits of therapy.
| Marker | Lab Normal Range | What GLP-1 Users Should Know |
|---|---|---|
| Serum creatinine (men) | 0.7 to 1.3 mg/dL | Indian men's muscle mass slightly lower; borderline values need context |
| Serum creatinine (women) | 0.5 to 1.1 mg/dL | Pregnancy changes values significantly |
| eGFR (estimated GFR) | Above 60 mL/min/1.73m² for normal | CKD stages 1 through 5 based on this |
| Blood urea nitrogen (BUN) | 7 to 25 mg/dL | Rises with dehydration or high protein intake |
| Uric acid (men) | 3.5 to 7.2 mg/dL | Above 6 mg/dL on GLP-1 requires monitoring |
| Uric acid (women) | 2.6 to 6.0 mg/dL | Above 5 mg/dL on GLP-1 requires monitoring |
What GLP-1 does to kidneys: GLP-1 medications protect kidney function in patients with diabetic kidney disease — a major benefit. The CREDENCE and DAPA-CKD trials showed reduction in kidney disease progression. However, in patients with severe kidney impairment (eGFR below 15 mL/min), semaglutide requires dose adjustment and tirzepatide has limited data.
The eGFR formula problem: Indian labs use different eGFR formulas — MDRD or CKD-EPI. Some labs still use the older Cockcroft-Gault formula. These give different results for the same creatinine value. Ask your lab which formula they use. The RSSDI recommends CKD-EPI as the most accurate for Indian adults.
Uric acid in Indian patients: Indians tend to have higher baseline uric acid levels, partly due to dietary patterns. GLP-1 medications mildly reduce uric acid as a secondary effect. If your uric acid is elevated and you develop joint pain on GLP-1, discuss gout risk with your doctor.
| Test | Lab Normal | Clinical Notes |
|---|---|---|
| TSH | 0.5 to 5.0 mIU/L (varies by lab) | Labs vary between 0.4–4.0 and 0.5–5.5 |
| Free T4 | 0.8 to 1.8 ng/dL | More reliable than total T4 |
| Free T3 | 2.3 to 4.2 pg/mL | Less commonly ordered; useful in specific cases |
What GLP-1 requires for thyroid monitoring: All GLP-1 medications carry a black box warning for medullary thyroid carcinoma (MTC) risk in rodent studies. No confirmed cases in humans have been definitively attributed to GLP-1. However, patients with personal or family history of MTC or Multiple Endocrine Neoplasia Type 2 (MEN2) should not use GLP-1 medications.
Thyroid screening on GLP-1: Your doctor should check TSH before starting and periodically during treatment. Hypothyroidism is extremely common in India — RSSDI estimates 42 million Indians have thyroid disease, majority undiagnosed.
Important: The TSH reference range varies significantly between Indian labs. Some labs use 0.5 to 5.0 mIU/L; others use 0.4 to 4.0 mIU/L. A TSH of 4.5 mIU/L would be "normal" on one report and "borderline" on another. Ask your doctor about the lab's specific reference range, not just whether you are "normal."
| Marker | Indian Lab Normal | Clinical Reality |
|---|---|---|
| Vitamin B12 | 200 to 900 pg/mL | Neurological symptoms can occur below 400 pg/mL; functional deficiency at 200 to 350 pg/mL |
| Folate | Above 4 ng/mL | Indian vegetarians frequently deficient |
Why this matters for GLP-1 users:
What to do: If your B12 is below 350 pg/mL, discuss supplementation with your doctor regardless of what the lab's reference range says. Oral cyanocobalamin 500 mcg to 1,000 mcg daily is commonly recommended in India (methylcobalamin is also available and preferred by some).
| Marker | Normal | What to Watch on GLP-1 |
|---|---|---|
| Haemoglobin (men) | 13.5 to 17.5 g/dL | Falling Hb suggests nutritional deficiency |
| Haemoglobin (women) | 12.0 to 15.5 g/dL | Indian women: NFHS-5 shows 57% are anaemic at baseline |
| White blood cells (WBC) | 4,000 to 11,000 cells/mcL | Mild reduction possible on GLP-1; watch for persistent low values |
| Platelets | 1.5 to 4.0 lakh cells/mcL | Usually unaffected |
Indian anaemia context: The NFHS-5 (2019-21) found 57% of Indian women aged 15 to 49 are anaemic. When these women start GLP-1 medications and eat 30% less food, iron deficiency can worsen significantly. Falling haemoglobin on GLP-1 is a sign that dietary iron intake is insufficient — discuss supplementation and iron-rich food inclusion with your doctor or dietitian.
1. Trusting "normal" without context. A B12 of 220 pg/mL is flagged as "normal" by most Indian labs but is functionally inadequate for many patients. Always discuss values near the lower limit of normal with your doctor, not just flagged values.
2. Comparing values between labs. Switching from SRL to Metropolis to Dr Lal PathLabs between test cycles introduces variability from different analysers, reagents, and reference ranges. Track the trend within the same lab where possible.
3. Panicking about single abnormal values. Isolated mildly elevated ALT or a slightly high creatinine on one report often requires repeat testing, not immediate alarm. Ask your doctor whether a repeat test in 4 to 6 weeks is appropriate.
4. Ignoring units. Some Indian labs report glucose in mg/dL, others in mmol/L. Some report creatinine in mg/dL, others in mcmol/L. Misreading units leads to serious misinterpretation. Always check the unit column.
5. Assuming GLP-1 effects are always improvement. While GLP-1 medications improve most metabolic markers, some values can temporarily worsen at the start — particularly liver enzymes in fatty liver disease, or creatinine in patients with borderline kidney function starting a weight-loss-induced fluid shift. These changes are usually transient and require monitoring, not panic.
Q: My HbA1c was 6.2% before starting GLP-1 and is now 5.9% after 6 months. My lab says both are "normal." Is this significant? A: Yes, a drop from 6.2% to 5.9% is a meaningful improvement. It represents a reversal of prediabetes trajectory. Your doctor should note and celebrate this progress even though both values fall within the lab's "normal" range.
Q: My LDL is 128 mg/dL and my lab marks it as normal. My doctor says it needs to come down. Who is right? A: Your doctor. For a person with Type 2 diabetes on GLP-1, the target LDL is below 100 mg/dL — or below 70 mg/dL if there is existing heart disease. The lab's "normal" of below 130 mg/dL is a population average, not a treatment target for people with diabetes.
Q: My creatinine is 1.4 mg/dL and my lab flags it as high. I'm on GLP-1. Should I be worried? A: Not necessarily, but this requires your doctor's assessment. Creatinine of 1.4 mg/dL in a woman is more concerning than in a man. Your eGFR (estimated from creatinine, age, and sex) is the more useful kidney function indicator. Ask your doctor for the eGFR calculation.
Q: How often should I repeat blood tests on GLP-1? A: The standard monitoring schedule recommended by RSSDI and most Indian endocrinologists is: full blood panel at baseline before starting, then HbA1c and fasting glucose at 3 months, then full panel (including liver, kidney, lipids, thyroid) every 6 to 12 months once stable. More frequent testing may be needed if you are on other medications (especially insulin) or have existing organ disease.
Contact your doctor promptly if you have new blood test results showing:
Remember: Consult your healthcare provider before starting any medication or interpreting medical test results on your own. This article is for informational purposes only and is not a substitute for personalised medical advice from a qualified doctor.
